Cowen & Co
http://www.cowen.com/default.htmlCowen and Company offers investment banking services, including equity research, equity and convertible debt financings, mergers and acquisitions advisory services, and restricted security sales.
-
SpringWorks Therapeutics Inc. (SWTX) prices 9.48M share offering at $29
-
SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
-
SpringWorks Therapeutics (SWTX) Announces $250M Proposed Public Offering of Common Stock
-
SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock
-
SpringWorks Therapeutics to Participate in the TD Cowen 4th Annual Oncology Innovation Summit
-
SpringWorks Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
-
SpringWorks Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
-
SpringWorks Therapeutics to Present at Upcoming Investor Conferences
-
SpringWorks Therapeutics to Present at Upcoming Investor Conferences
-
SpringWorks Therapeutics to Present at the Cowen 2nd Annual Oncology Innovation Summit
-
SpringWorks Therapeutics to Present at the Cowen 2nd Annual Oncology Innovation Summit
-
SpringWorks Therapeutics to Present at Upcoming Investor Conferences
-
SpringWorks Therapeutics to Present at Upcoming Investor Conferences
-
SpringWorks Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
SpringWorks Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
SpringWorks Therapeutics Inc. (SWTX) Prices 4.9M Share Common Offering at $51/Sh
-
SpringWorks Therapeutics Announces Pricing of Public Offering of Common Stock
-
SpringWorks Therapeutics Announces Pricing of Public Offering of Common Stock
-
SpringWorks Therapeutics Inc. (SWTX) Announces Proposed $150M Public Offering of Common Stock
-
SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock
-
SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock
-
SpringWorks Therapeutics Inc. (SWTX) Enters Sponsored Research Agreement with Fred Hutchinson Cancer Research Center to Further Evaluate Nirogacestat as BCMA Potentiator in Multiple Myeloma
-
SpringWorks Therapeutics Enters into Sponsored Research Agreement with Fred Hutchinson Cancer Research Center to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple Myeloma
-
SpringWorks Therapeutics Enters into Sponsored Research Agreement with Fred Hutchinson Cancer Research Center to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple Myeloma
-
SpringWorks Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference
-
SpringWorks Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference
-
Cowen Starts Spring Works Therapeutics (SWTX) at Outperform
-
SpringWorks Therapeutics Announces Closing Of Initial Public Offering and Exercise in Full of the Underwriter’s Option to Purchase Additional Shares
-
SpringWorks Therapeutics Announces Closing Of Initial Public Offering and Exercise in Full of the Underwriter’s Option to Purchase Additional Shares
-
SpringWorks Therapeutics Inc. (SWTX) IPO Opens 36% Higher
-
SpringWorks Therapeutics Inc. (SWTX) Prices 9M Share IPO at $18/Sh
-
SpringWorks Therapeutics Announces Pricing Of Initial Public Offering

